Only in the case of recurrent or metastatic HNSCC (R/M HNSCC), Cetuximab, small molecule EGFR inhibitors, and novel immune checkpoints inhibitors such as Pembrolizumab and Nivolumab are included in the treatment [59]. Here, EGFR is linked to head and neck squamous cell carcinoma.